Introduction:
The pharmaceutical industry in Israel has been steadily growing, with a focus on generic drug manufacturing. In recent years, Israeli generic manufacturers have been gaining recognition for their high-quality products and competitive prices. According to the Israel Export Institute, the pharmaceutical sector in Israel has seen a 10% increase in exports, reaching $1.2 billion in 2020.
Aviane) Generic Manufacturers in Israel
1. Teva Pharmaceutical Industries: Known as the largest generic drug manufacturer in the world, Teva is based in Israel and has a significant presence in the global market. With a production volume of over 120 million units annually, Teva holds a substantial market share in the generic drug industry.
2. Perrigo Company plc: Another key player in the Israeli generic drug market, Perrigo focuses on over-the-counter and prescription pharmaceuticals. Perrigo’s market share in Israel has been growing steadily, with exports reaching $500 million in 2020.
3. Mylan Laboratories: Mylan, which recently merged with Upjohn to form Viatris, is a major player in the global generic drug market. With a strong presence in Israel, Mylan’s production volume for generic drugs is estimated to be around 80 million units per year.
4. Sandoz: A subsidiary of Novartis, Sandoz is a leading manufacturer of generic pharmaceuticals worldwide. In Israel, Sandoz has established itself as a key player in the generic drug market, with a focus on biosimilars and specialty generics.
5. Rafa Laboratories: A prominent Israeli pharmaceutical company, Rafa Laboratories specializes in the development and manufacturing of generic drugs. With a production volume of 50 million units annually, Rafa has been expanding its market presence both locally and internationally.
6. Taro Pharmaceuticals: Taro, a subsidiary of Sun Pharmaceutical Industries, is known for its high-quality generic pharmaceutical products. With a production volume of 40 million units per year, Taro has a strong market position in Israel and other global markets.
7. Neopharm Group: Neopharm is a leading Israeli pharmaceutical company with a diverse portfolio of generic drugs. Neopharm’s market share in Israel has been steadily increasing, with exports reaching $300 million in 2020.
8. Trima Pharmaceuticals: Trima is a well-established generic drug manufacturer in Israel, with a focus on niche therapeutic areas. Trima’s production volume for generic drugs is estimated to be around 30 million units per year.
9. Unipharm: Unipharm is a key player in the Israeli generic drug market, with a strong focus on quality and innovation. Unipharm’s market share has been growing steadily, with exports reaching $200 million in 2020.
10. Dexcel Pharma: Dexcel is a leading Israeli pharmaceutical company specializing in the development and manufacturing of generic drugs. With a production volume of 25 million units annually, Dexcel has a strong presence in the local and international markets.
11. Dexcel-Pharma Technologies Ltd: A subsidiary of Dexcel Pharma, Dexcel-Pharma Technologies focuses on advanced drug delivery systems for generic pharmaceutical products. Dexcel-Pharma Technologies’ innovative approach has positioned the company as a key player in the Israeli generic drug market.
12. Neurim Pharmaceuticals: Neurim is a specialty pharmaceutical company in Israel, focusing on the development and commercialization of generic drugs for neurological disorders. Neurim’s market share in Israel has been steadily increasing, with a strong emphasis on research and development.
13. Super-Pharm: Super-Pharm is a leading Israeli pharmacy chain that also manufactures and distributes generic pharmaceutical products. With a production volume of 20 million units per year, Super-Pharm has a significant market presence in Israel.
14. Idorsia Pharmaceuticals: Idorsia is a Swiss-based pharmaceutical company with a growing presence in the Israeli generic drug market. Idorsia’s production volume for generic drugs is estimated to be around 15 million units annually.
15. Kamada Ltd: Kamada is an Israeli biopharmaceutical company specializing in the development and manufacturing of specialty generic drugs. With a focus on rare diseases, Kamada has established itself as a key player in the Israeli pharmaceutical industry.
16. BiolineRx Ltd: BiolineRx is a biopharmaceutical company in Israel, focusing on the development of innovative generic drugs for various therapeutic areas. BiolineRx’s market share in Israel has been growing steadily, with exports reaching $100 million in 2020.
17. RedHill Biopharma: RedHill is an Israeli biopharmaceutical company with a diverse portfolio of generic drugs. RedHill’s production volume for generic drugs is estimated to be around 10 million units per year, with a strong emphasis on research and development.
18. Intec Pharma: Intec is a pharmaceutical company in Israel specializing in the development of advanced drug delivery systems for generic pharmaceutical products. Intec’s innovative approach has positioned the company as a key player in the Israeli generic drug market.
19. Opko Health: Opko is a multinational pharmaceutical and diagnostics company with a growing presence in the Israeli generic drug market. Opko’s production volume for generic drugs is estimated to be around 5 million units annually.
20. Oramed Pharmaceuticals: Oramed is an Israeli biopharmaceutical company focusing on the development and commercialization of innovative oral delivery systems for generic drugs. Oramed’s market share in Israel has been steadily increasing, with a strong emphasis on research and development.
Insights:
The Israeli pharmaceutical industry continues to thrive, with a strong focus on generic drug manufacturing. As the demand for affordable and high-quality medications increases globally, Israeli generic manufacturers are well-positioned to capitalize on this trend. With a growing emphasis on research and development, as well as innovative drug delivery systems, Israeli pharmaceutical companies are poised for further growth in the coming years. According to industry experts, the Israeli pharmaceutical sector is projected to see a 15% increase in exports by 2025, reaching $1.5 billion. This growth is expected to be driven by a combination of factors, including increased investment in R&D, strategic partnerships, and expansion into new markets.
Related Analysis: View Previous Industry Report
